SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing heightened investor interest as the community debates its role as a defensive haven amidst broader geopolitical tensions in the Middle East and concerns over upcoming CMS Medicare Advantage reimbursement rate announcements. While some traders are capitalizing on short-term volatility through option strategies and potential gap fills, others are closely watching institutional disclosures and debating the long-term impact of regulatory pressures on the managed care sector.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is experiencing heightened trading activity as the community anticipates critical updates on the NASA Lunar Terrain Vehicle contract and forward-looking guidance in the upcoming earnings report. Traders are actively debating the stock's potential for a short squeeze, fueled by bullish sentiment regarding the company's backlog expansion and its pivot toward deep space infrastructure.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund is trending due to significant price volatility and heavy trading volume following its recent NYSE listing, which provides retail investors with rare access to high-profile private AI companies like Anthropic, OpenAI, and SpaceX. Community discussion is polarized between optimistic traders anticipating further momentum and skeptical voices concerned about the fund trading at a substantial premium to its net asset value and the impact of the six-month lockup on existing shareholders.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is facing intense volatility driven by geopolitical tensions in the Middle East and concerns over supply chain impacts, despite strong fundamental growth in AI memory demand. Community discussions are currently split between those frustrated by aggressive market manipulation and short-term volatility, and others who remain bullish on the long-term potential of the company's HBM capacity and upcoming inclusion in the S&P 100.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is seeing heightened volatility as the market reacts to conflicting narratives surrounding the company's namesake and his claims of productive diplomatic talks with Iran. Investors are closely monitoring these statements, as community sentiment remains deeply polarized between those betting on stock stabilization and others skeptical of the administration's claims.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is generating intense retail interest and community debate as investors navigate recent earnings volatility, insider share sales, and anticipation surrounding a potential strategic partnership with POSCO. While some vocal retail investors are attempting to coordinate a short squeeze and accumulate shares at current support levels, others remain cautious due to debt concerns and ongoing leadership scrutiny.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is trending following a massive 37% year-over-year surge in January revenue, significantly outperforming initial growth targets. Investors are actively discussing the stock's record-breaking momentum, its role as the backbone of global AI infrastructure, and the potential impact of recent tariff relief on its U.S. foundry expansion.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is currently generating intense debate among retail investors regarding a perceived valuation disconnect, with many pointing to the company's substantial cash position and strategic asset pipeline versus its suppressed stock price. The community is actively discussing potential catalysts like upcoming US manufacturing tax credits and possible M&A activity, while simultaneously expressing deep frustration over alleged market manipulation and a lack of clear communication from leadership regarding shareholder value.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

4Chan is trending as the community rallies around its status as the 'bitcoin of memecoins' and the foundational source of internet culture, positioning it as an uncensorable index for the broader meme sector. Traders are actively debating its high-volatility potential and long-term utility, with many emphasizing the token's thick liquidity and zero-heavy supply as a strategic hedge against broader market instability.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The DIA is trending as investors react to increased market volatility driven by escalating geopolitical tensions in the Middle East and concerns over persistent inflation. Community sentiment is deeply divided, with many traders expressing frustration over conflicting reports regarding potential ceasefire talks while debating the long-term economic impact of the conflict on energy prices and overall market stability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BIAF Stock Surges 85%, Breaks 200-DMA For The First Time In Nearly A Year – Here’s What’s Driving The Rally

The stock has been on a sharp uptrend, gaining more than 160% over the past week on the back of bullish CyPath Lung estimates.

Equity

<ul class="summary-bullets"><li>Michael Hearne has been appointed Chief Financial Officer, replacing Joe Miller.</li><li>Decision to remove Greenleaf and install Tang as CEO represents a “complete validation” of concerns raised for nearly three years, major shareholder MKT Capital said in a statement.</li><li>The company is looking to initiate a clinical study of Aritinercept for an autoimmune disease in the first half of 2026.&nbsp;</li></ul>Aurinia Pharmaceuticals (AUPH) drew strong retail interest on Monday after naming Kevin Tang as Chief Executive Officer, fueling investor hopes of a “new positive era” for the company.<a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> was up more than 6% at the time of writing.Tang, who is also the Chair of the Board, will replace Peter Greenleaf, who has been the company’s CEO for the past 7 years. Tang, an industry veteran, previously served as Chairman of La Jolla Pharmaceutical Company from 2014 through its acquisition by Innoviva in 2022.In 2013, Tang founded Odonate Therapeutics and served as its Chairman and CEO through 2022. Mr. Tang also co-founded Ardea Biosciences in 2006 and Heron Therapeutics in 2009. From 2009 through its acquisition by Keenova Therapeutics in 2010, Tang served as Director of Penwest Pharmaceuticals Co.Among other changes, Michael Hearne has been appointed Chief Financial Officer, replacing Joe Miller. Meanwhile, Ryan Cole was appointed as Chief Operating Officer, and Thomas Wei took over as Chief Scientific Officer.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment flipped to ‘bullish’ from ‘bearish,’ amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/AUPH_jpg_4ef07ce8ea.webp" alt="AUPH.jpg">One user speculated on the implications of the management change for the company, akin to the potential for it to go private.<stembedurl>https://stocktwits.com/US_Bull/message/648264487</stembedurl>Another user said, “Hopefully this starts the beginning of a new positive era”.<stembedurl>https://stocktwits.com/cjohoya/message/648275231</stembedurl>In 2021, Aurinia Pharmaceuticals launched LUPKYNIS, an FDA-approved oral treatment for adults with active Lupus Nephritis. The company also plans to begin a clinical study of Aritinercept for an autoimmune disease in the first half of 2026. Aurinia reported its first full-year profit in December 2024.<h2 class="st-heading-2">MKT’s Statement On Management Changes</h2>MKT Capital, a major long-term shareholder of Aurinia, issued a statement following the appointment of Kevin Tang as CEO.“Today marks a watershed moment for Aurinia shareholders. Since 2019, we have tirelessly advocated for accountability, disciplined capital allocation, and genuine alignment between management and the true owners of this Company – its shareholders. The Board’s decision to remove CEO Peter Greenleaf and his executive team, and to install Chair Kevin Tang as CEO, represents a complete validation of the concerns we have raised for nearly three years,” said Antoine Khalife, Founder of MKT Capital.In April 2025, MKT Capital announced its intention to withhold support for Greenleaf at the 2025 Annual General Meeting.Year-to-date, the stock has fallen 6.5%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nvda-stock-200-dma-rebound-ai-factories-deal/cZ3mgN2RI0Z">NVDA Stock Rebounds But Remains Below Key Support For Second Session: Retail Sees Massive Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aurinia Pharmaceuticals logo is seen displayed on a smartphone screen

AUPH Stock Rallies After CEO Shake-Up: Retail Bulls Bet On Turnaround

Aurinia Pharmaceuticals named Kevin Tang as its Chief Executive Officer, replacing Peter Greenleaf.

<ul class="summary-bullets"><li>NVIDIA is struggling to reclaim a key technical ground after slipping below its 200-day moving average on Friday.</li><li>Taiwanese outlet cnYES reported that NVIDIA is revising the design of its Feynman AI chips due to limited production capacity on TSMC’s advanced A16 process.</li><li>NVIDIA has outperformed all but two of its ‘Mag 7’ peers so far this year.</li></ul>NVIDIA (NVDA) struggled below key technical levels, with the stock staying under its 200-day moving average. It had breached this for the first time since May 2025 in the previous session.Despite slipping below a crucial level, <a href="https://stocktwits.com/symbol/NVDA">NVDA stock</a> rebounded more than 2% on Monday as the chipmaker doubled down on its long-term AI ambitions.&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://in.tradingview.com/chart/teA7VKVN/?symbol=NYSE%3ANVDA"><img src="https://news.stocktwits-cdn.com/NVDA_jpg_634432b9a0.webp" alt="NVDA.jpg"></a>Source: TradingViewMeanwhile, retail sentiment for NVDA on Stocktwits turned ‘neutral’ from ‘bullish’ a day earlier.<img src="https://news.stocktwits-cdn.com/NVDA_S_jpg_81478f7d38.webp" alt="NVDA S.jpg"><h2 class="st-heading-2">What Did Stocktwits Users Say?</h2>Chatter was mixed. One user said the stock is overdue for a 40%-70% run.<stembedurl>https://stocktwits.com/WunDumFuc/message/648265673</stembedurl>Another user cited broader market weakness as the cause of the stock’s underperformance.<stembedurl>https://stocktwits.com/I_am_back_2day/message/648272513</stembedurl>Despite trending down, NVDA shares have outperformed all but two of its peers in the “Magnificent 7” group so far this year. The stock declined 5.8% so far in 2026. Only Google (-5%) and Apple (-5.3%) fared better.<h2 class="st-heading-2">Partnership with Emerald AI To Develop AI Factories</h2>On Monday, the chipmaker teamed up with Emerald AI and energy firms including AES Corporation (AES), Constellation Energy (CEG), Invenergy, NextEra Energy (NEE), Nscale Energy &amp; Power, and Vistra Corp. (VST) to develop a new class of AI factories.The facilities are designed to connect to power grids more quickly and can also operate as flexible energy assets to support grid stability. The AI factories will rely on co-located power generation and storage to bring capacity online quickly before transitioning to full grid integration.<h2 class="st-heading-2">NVIDIA’s Feynman AI Chips Production Under Pressure</h2>Earlier on Monday, Taiwanese outlet cnYES <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-hits-a-snag-next-gen-feynman-chip-reportedly-faces-design-rethink-on-tsmc-s-a16-capacity-crunch/cZ3mGgQRIiH">reported</a> that NVIDIA is revising the design of its upcoming Feynman AI chips due to limited production capacity on TSMC’s advanced A16 process. NVIDIA was earlier expected to be the lead customer for TSMC’s 1.6nm node, slated for mass production later this year. However, capacity constraints are now forcing a shift in strategy.Under the potential revised plan, only the most critical chip components will use the A16 process, while other parts will be produced using the older N3P (3nm) node.NVIDIA has also been in the spotlight after the U.S. indicted three individuals linked to Super Micro Computer Inc (SMCI), including co-founder Yih-Shyan Liaw, over their alleged involvement in a scheme to smuggle $2.5 billion worth of NVIDIA equipment&nbsp;into China.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-lexicon-obesity-drug-lx9851-phase-1-trial/cZ3ma9ORI0Q">Novo Nordisk Advances Obesity Pipeline With Early-Stage Oral Drug Trial From Lexicon Deal</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Nvidia corporate logo is featured at the Fira Gran Via during the Mobile World Congress in Barcelona, Spain

NVDA Stock Rebounds But Remains Below Key Support For Second Session: Retail Sees Massive Upside

NVIDIA announced on Monday that it partnered with Emerald AI to develop a new class of AI factories.

<ul class="summary-bullets"><li>Critical Metals said the acquisition will add new exploration assets and support its Tanbreez rare earth project.</li><li>USA Rare Earth and Arnold Magnetic will work to produce magnets from samarium-cobalt and neodymium-iron-boron.</li><li>Earlier in the month, USA Rare Earth announced the acquisition of the remaining stake in Texas Mineral Resources for $73 million.</li></ul>Critical Metals Corp. (CRML) and USA Rare Earth (USAR) were in the limelight on Monday following crucial developments that boost their rare-earth pipelines.&nbsp;At the time of writing, <a href="https://stocktwits.com/symbol/CRML">CRML stock</a> gained 4% while <a href="https://stocktwits.com/symbol/USAR">USAR shares</a> jumped more than 5%.Critical Metals is set to strengthen its presence in Greenland after announcing it would acquire a majority stake in construction, exploration, and logistics firm 60° North Greenland ApS. The deal adds new exploration assets while also supporting its Tanbreez rare earth project.This comes after Critical Metals’ board approved a $30 million acceleration program to fast-track development of the Tanbreez project earlier this month. The initiative is targeting the first ore production by late 2028 or early 2029.The program includes up to 6,000 meters of drilling and plans to significantly expand the resource base, alongside bulk sampling and metallurgical testing. Tanbreez is one of the world’s largest known rare earth deposits and benefits from strong logistics near North Atlantic shipping routes. Rare earths are critical for electric vehicles, renewable energy, and defense technologies.<h2 class="st-heading-2">USAR’s Tie-Up With Arnold Magnetic Technologies</h2>Separately, USA Rare Earth announced a sales and distribution agreement with Compass Diversified’s (CODI) unit, Arnold Magnetic Technologies. The partnership allows both companies to market each other’s rare earth magnet products. The two companies will work to produce magnets from samarium-cobalt (SmCo) and neodymium-iron-boron (NdFeB).Earlier in the month, USAR said it would acquire the remaining stake in Texas Mineral Resources in an all-stock deal valued at about $73 million. The transaction will give USA Rare Earth full ownership of the Round Top project in Texas, a major domestic source of critical minerals.USA Rare Earth said the Trump administration would support a $1.6 billion debt-and-equity funding package to help develop its Texas mine and magnet facility, according to a Reuters report earlier in March.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for USAR turned ‘neutral’ from ‘bearish’ a day earlier, while sentiment remained ‘bearish’ for CRML.One user called CRML’s acquisition of 60° North Greenland a “hugely positive news.”<stembedurl>https://stocktwits.com/infomike/message/648304287</stembedurl>Another user called USAR an “under the radar microcap.”<stembedurl>https://stocktwits.com/zoyhen_trd/message/648295921</stembedurl>Year-to-date, USAR shares have surged nearly 40% while CRML stock has edged roughly 13% higher.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/auph-stock-jumps-ceo-shake-up-aurinia-tang-greenleaf/cZ3mLhSRI0p">AUPH Stock Rallies After CEO Shake-Up: Retail Bulls Bet On Turnaround</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Samples of rare-earth minerals from Baiyun'ebo or Bayan Obo mining district are on display at the Institute of Geology and Geophysics, Chinese Academy of Sciences (IGGCAS) on May 17, 2025, in Beijing, China. (Photo by VCG/VCG via Getty Images)

Two Rare Earth Stocks Are Gaining Today - Here's Why

Critical Metals is set to acquire a majority stake in a Greenland-based exploration firm, while USA Rare Earth signed a sales agreement with Arnold Magnetic.

CRML, USAR Stocks Rise: What’s Driving Them Higher?

<ul class="summary-bullets"><li>The start of the trial triggered a second $10 million milestone payment to Lexicon.</li><li>The Phase 1 study will evaluate safety and dosing in 96 overweight or obese participants.</li><li>The trial is expected to be completed in early 2027, Novo said.</li></ul>Novo Nordisk (NVO) is pushing deeper into next-gen obesity treatments. The drugmaker announced on Monday that it has initiated a Phase 1 study of LX9851, Lexicon Pharmaceuticals’ oral non-incretin drug candidate for obesity and related metabolic disorders.&nbsp;This adds to Novo’s obesity treatment pipeline, which also features the semaglutide injection, famously known as Wegovy.&nbsp;At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/NVO">NVO shares</a> climbed 1%, while&nbsp;<a href="https://stocktwits.com/symbol/LXRX">Lexicon Pharmaceuticals’ (LXRX) stock</a> traded over 5% higher.<h2 class="st-heading-2">Novo’s $10 Million Milestone Payment To Lexicon</h2>The start of the trial triggered a second $10 million milestone payment to Lexicon under their licensing deal signed in March 2025. The agreement gives Novo Nordisk exclusive global rights to develop and commercialize the drug, with Lexicon eligible to receive up to $1 billion in total milestone payments, as well as royalties on future sales.The Phase 1 study will evaluate safety and dosing in 96 overweight or obese participants. The trial is expected to be completed in early 2027.“LX9851 offers a novel approach to the treatment of obesity and related metabolic conditions. It is an important addition to our pipeline of potential treatment options as we look to meet the diverse needs of people living with obesity, diabetes and their associated comorbidities,” said Jacob Sten Petersen, Senior Vice President and Head of Global Research at Novo Nordisk.&nbsp;<h2 class="st-heading-2">Lilly’s&nbsp;Experimental Diabetes Pill Outperforms Oral Semaglutide&nbsp;</h2>This comes days after&nbsp;Eli Lilly and Company (LLY) announced that its experimental diabetes pill, Orforglipron, outperformed oral semaglutide in a large Phase 3 study, delivering stronger reductions in blood sugar and greater weight loss over 52 weeks. Lilly has filed the drug for approval in more than 40 countries and plans to submit it in the U.S. later this year.Drug developers are racing to tap the booming obesity market, currently led by injectables like Wegovy and Eli Lilly’s Zepbound.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for NVO and LXRX remained in the ‘bearish’ zone over the past 24 hours.One user called LXRX’s price point “attractive.”<stembedurl>https://stocktwits.com/macrossluvsrobotech/message/648275638</stembedurl>Another user was skeptical about Novo’s forecast.<stembedurl>https://stocktwits.com/Golferhack12/message/648300759</stembedurl>Year-to-date, NVO stock fell 29% while LXRX shares have gained more than 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk Advances Obesity Pipeline With Early-Stage Oral Drug Trial From Lexicon Deal

The trial is part of a licensing deal between Novo and Lexicon that allows Novo to develop and commercialize the drug.

<ul class="summary-bullets"><li>The study found that patients maintained strong treatment responses with dosing every 3 or 6 months.</li><li>The drug also showed continued improvement in skin lesions and itch symptoms across the full study population, Apogee said.</li><li>The biotech firm added that results from Part B of its APEX trial are expected in the second quarter of fiscal 2026.</li></ul>Shares of Apogee Therapeutics (APGE) popped 18% in pre-market trading on Monday after the biotech firm said its lead drug, Zumilokibart, showed positive 52-week maintenance results in a Phase 2 trial for patients with moderate-to-severe Atopic Dermatitis, a type of skin condition.The study found that patients maintained strong treatment responses with dosing every 3 or 6 months, suggesting the therapy could require less frequent dosing than current options.Among patients who responded by Week 16, 75% on three-month dosing and 85% on six-month dosing maintained at least a 75% reduction in EASI scores. The drug also showed continued improvement in skin lesions and itch symptoms across the full study population. The therapy was generally well tolerated, with common side effects including conjunctivitis and upper respiratory infections, Apogee said.“Consistent maintenance of response as well as deepening of responses over time were observed across key endpoints for both the 3- and 6-month dosing regimens, demonstrating a highly differentiated profile that could allow treatment to be administered as few as two times per year, compared with up to 26 injections annually for currently available therapies,” said Carl Dambkowski, Chief Medical Officer of Apogee.<h2 class="st-heading-2">Part B Of Phase 2 Study Expected In Q2 2026</h2>Apogee said that Part B of its APEX trial is a placebo-controlled study evaluating different doses of Zumilokibart, with 347 patients split across high, medium, low, and placebo groups. Results from the 16-week study are expected in the second quarter of 2026, earlier than the company’s initial timeline of the second half of the year.Based on the current findings and regulatory progress, the company aims to start Phase 3 trials in the second half of 2026, with a potential launch targeted for 2029.<h2 class="st-heading-2">How Did Stockwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.One user highlighted that for biotech stocks, clearing a coil squeeze could mean a sharp upside.<stembedurl>https://stocktwits.com/XpandXalpha81/message/648262854</stembedurl>More than 2 million shares changed at the time of writing, more than twice the average volumes of 0.8 million, according to Stocktwits data.Another user said that despite the stock doubling in value over the past year, it is only the “beginning.”<stembedurl>https://stocktwits.com/Pika_Capital/message/648277177</stembedurl>Year-to-date, the stock has climbed around 6%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Biotech Stock Is Soaring Today On Positive Trial Results

The company announced positive Phase 2 trial results for the treatment of patients with moderate-to-severe Atopic Dermatitis.

Why Did APGE Stock Jump 22% Today?

<ul class="summary-bullets"><li>The probe was linked to the company’s SPAC merger and PIPE financing disclosures.</li><li>In 2021, short-seller J Capital Research published an article raising concerns regarding Faraday Future’s production plans, finances, and R&amp;D.</li><li>The company said it will continue with its long-term strategy, including a roadmap focused on business growth and AI-driven development.</li></ul>Shares of Faraday Future Intelligent Electric (FFAI) soared more than 50% in pre-market trading on Monday after the company said a “years-long investigation” by the U.S. Securities and Exchange Commission had ended without any enforcement action against the firm or its executives.The probe, which dates back to 2021, was linked to the company’s Special Purpose Acquisition Company (SPAC) merger and Private Investment in Public Equity (PIPE) financing disclosures.The SEC had earlier issued Wells Notices to the company, its founder, Jia Yueting, and its President, Jerry Wang. A Wells Notice is a warning from the SEC that it may bring charges for possible securities law violations. It gives the recipient a chance to respond before any final decision is made.<h2 class="st-heading-2">“New EV Scam in Town”</h2>In 2022, the SEC subpoenaed some Faraday Future executives as part of a probe into inaccurate statements made to investors. Back then, CEO Carsten Breitfield and founder Jia Yueting saw their base salaries reduced.In 2021, short-seller J Capital Research published an article, “Move Over Lordstown: There’s a New EV Scam in Town,” targeting Faraday Future. The article, which was rejected by the EV maker, raised concerns about its production plans, finances, and R&amp;D efforts.Faraday Future went public on the Nasdaq in July 2021 through a SPAC merger at an offering price of $13.78.<h2 class="st-heading-2">Faraday To Kick On With Long-Term Growth Strategy</h2>Faraday Future said the development removes a major overhang that had weighed on investor sentiment and limited the company’s ability to secure funding and partnerships. The company added that the investigation had made it difficult to work with institutional investors, investment banks, and strategic partners due to compliance concerns.With the probe closed, the company expects to advance financing discussions. It will go ahead with its long-term strategy, including a multi-phase roadmap focused on business growth and AI-driven development.<h2 class="st-heading-2">Faraday’s Listing Challenges</h2>According to an SEC filing on Friday, Faraday Future Intelligent received a notice from the Nasdaq Stock Market for failing to maintain a minimum share price of $1 over 30 consecutive trading days. The company has 180 days, until Sept. 16, 2026, to regain compliance with the listing requirement. If the company fails to comply, it could face delisting.<a href="https://stocktwits.com/symbol/FFAI">FFAI shares</a> have traded below $1 since Feb. 5, 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for FFAI remained in the ‘extremely bullish’ zone over the past 24 hours. Message volumes increased by 50% according to Stocktwits data.<figure class="image"><img src="https://news.stocktwits-cdn.com/FFAI_jpg_c758c08c8b.webp" alt="FFAI.jpg" width="856" height="96"><figcaption>FFAI's Sentiment Meter and Message Volumes at Pre-Market on March, 23, 2026 | Source: Stocktwits</figcaption></figure>However, chatter was mixed. While one expects the stock to climb to $3 from its current price of $0.4, another user sees FFAI as a “pump and dump” stock.<stembedurl>https://stocktwits.com/Aburose/message/648247735</stembedurl><stembedurl>https://stocktwits.com/leoleolee/message/648249157</stembedurl>The stock has been under heavy selling pressure in 2026, shedding more than 70%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Faraday Future logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did FFAI Stock Soar 50% In Pre-Market Today?

The company said the SEC will not recommend any enforcement action after concluding an investigation dating back to 2021.

<ul class="summary-bullets"><li>Jefferies upgraded the stock to ‘Hold’ from ‘Underperform’ and raised the price target to $49 from $30, according to The Fly.</li><li>The brokerage expects a demand uptick in Europe that could support SolarEdge’s earnings.</li><li>he Dutch TTF Natural Gas Futures have surged nearly 92% since the conflict began.</li></ul>Shares of SolarEdge Technologies (SEDG) jumped 13% on Friday to their highest levels since May 2024, after Jefferies said the company could potentially benefit from the volatility in energy markets caused by the conflict in the Middle East.<a href="https://stocktwits.com/symbol/SEDG">SEDG stock</a> is on track to post its sixth straight session of gains, and has surged more than 50% since the&nbsp;U.S.-Israeli strikes on Iran commenced on February 28.The company develops solar-based power products, including electric vehicle chargers, inverters, and various storage and backup options.<h2 class="st-heading-2">Jefferies Draws Parallels With Russia-Ukraine War</h2>On Friday, Jefferies upgraded SolarEdge to ‘Hold’ from ‘Underperform’ and raised the price target to $49 from $30, according to The Fly.As the conflict in the Middle East fuels volatility in European energy prices, the impact is comparable to the Russia-Ukraine conflict, which drove SolarEdge Technologies’ Europe revenue to $1.9 billion in 2023 from $630 million in 2020, Jefferies said.The brokerage expects a similar, though “not as dramatic,” demand uptick in Europe that could support earnings. According to SolarEdge’s financial statements for the full-year (FY) 2023, nearly two-thirds of its overall total electrical power capacity was shipped to Europe.Meanwhile, the Dutch TTF Natural Gas Futures,&nbsp;the European benchmark, have surged nearly 92% since the conflict began, while Brent Crude Futures for May 2026 deliveries have jumped around 53%.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘neutral’ from ‘bearish’ a day earlier, but chatter was largely bullish.One user urged picking up fresh positions.<stembedurl>https://stocktwits.com/Laundrup/message/648049539</stembedurl>Another user said the stock is also benefiting from its Nexis platform, launched a day earlier. The Nexis system combines a new three-phase inverter of up to 20kW, a modular battery, and a full-home backup system that can be easily installed.<stembedurl>https://stocktwits.com/Joseph_86/message/648093179</stembedurl>Year-to-date, the stock has gained around 75%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-aztr-stock-rising-today/cZ3Xs8uRILN">This Nano-Cap Pharma Stock Surged 80% Days After A Listing Warning — What’s Fueling the Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a SolarEdge Technologies logo is seen on a smartphone

This Mid-Cap Solar Stock Has Rallied 50% Since The Middle East Conflict Began – Here’s What Jefferies Said About Its Potential Europe Traction

SolarEdge shares are trading at a 22-month high, and are on track to gain for the sixth straight session.

Why Is SEDG Stock Rising Today? 

<ul class="summary-bullets"><li>NextEra Energy secured approval to develop up to 10 gigawatts of natural gas-powered projects.</li><li>The projects are aimed at meeting rising electricity demand, particularly from data centers and advanced manufacturing.</li><li>Earlier, the company also announced plans to build up to 15 gigawatts of data hub capacity by 2035.</li></ul>NextEra Energy Inc. (NEE) drew investor attention on Friday after announcing it had secured approval from President Donald Trump to develop up to 10 gigawatts of natural gas-powered projects in Texas and Pennsylvania.<a href="https://stocktwits.com/symbol/NEE">NEE shares</a> &nbsp;were trading around 1% lower.The move is tied to a broader U.S.-Japan trade agreement that includes a $550 billion investment commitment by the Asian country. The projects, jointly owned by U.S. and Japanese stakeholders, are aimed at meeting rising electricity demand, particularly from data centers and advanced manufacturing. They will be built and operated by NextEra.“Our hub strategy is designed to scale quickly and support rising demand while strengthening America's energy security—without increasing electricity costs for American households,” said John Ketchum, chairman, president and CEO of NextEra Energy.<h2 class="st-heading-2">Natural Gas Push</h2>NextEra Energy has been ramping up its push into natural gas-powered infrastructure. Last December, the company <a href="https://stocktwits.com/news-articles/markets/equity/nextera-exxon-mobil-team-up-on-massive-gas-powered-ai-energy-push/cLIpGs8REmx">entered</a> into a partnership with ExxonMobil to build a 1.2-gigawatt plant to supply power to major tech companies. NextEra also announced plans to build up to 15 gigawatts of data hub capacity by 2035, supporting clients such as Google and Meta Platforms Inc.The company is also expanding its gas footprint through the acquisition of Symmetry Energy Solutions and partnerships with Comstock Resources and Basin Electric Power Cooperative. Rising U.S. power demand, expected to grow sharply by 2030, is driving these investments.The deals come as U.S. electricity demand surges, driven by data centers that could strain grid capacity, with S&amp;P Global estimating consumption could rise by up to 25% by 2030.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘bearish’ zone over the past 24 hours.One user said the stock is undervalued at the moment.<stembedurl>https://stocktwits.com/scotttrader213/message/648043294</stembedurl>Year-to-date, the stock has gained around 13%For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of NextEra Energy, Inc. is displayed on a smartphone screen, in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Trump’s Approval For NextEra Energy’s Texas And Pennsylvania Projects Fails To Boost NEE Stock – Retail Says Shares Are ‘Undervalued’

The projects are a part of a broader $550 billion U.S.-Japan trade agreement.

<ul class="summary-bullets"><li>The funding includes a $10.5 million upfront offering and up to $20.9 million from warrant exercises.</li><li>The company plans to use the proceeds to advance new protein and peptide research programs.</li><li>Last week, Azitra received a notice from the NYSE for failing to meet its minimum stockholders’ equity requirement of $6 million.</li></ul>Shares of Azitra Inc. (AZTR) surged more than 80% on Friday, crossing over its 100-day moving average for the first time since June 2025, after the biopharmaceutical firm announced a private placement to raise over $31 million.<figure class="image"><a class="st-link-external" href="https://in.tradingview.com/chart/teA7VKVN/?symbol=AMEX%3AAZTR" target="_blank" rel="noopener noreferrer nofollow"><img src="https://news.stocktwits-cdn.com/aztr_jpg_0fe58a1f37.webp" alt="aztr.jpg" width="1345" height="849"></a></figure>Source: TradingViewOn Friday, <a href="https://stocktwits.com/symbol/AZTR">AZTR shares</a> recorded their biggest intraday gains since July 27, 2024.<h2 class="st-heading-2">Azitra To Advance New Protein And Peptide Research Programs</h2>Azitra said it is in the process of securing a financing deal worth up to $31.4 million to support its expansion into the cosmetic and cosmeceutical markets. The funding includes an initial $10.5 million offering through convertible preferred stock, with an additional $20.9 million tied to the potential exercise of warrants.The transaction is backed by institutional healthcare investors, including Stonepine Capital and Nantahala Capital.The company plans to use the proceeds to advance new protein and peptide research programs, using its microbial genetic engineering platform. Azitra aims to accelerate the development and commercialization of skincare solutions targeting issues such as dry skin and ageing.“We are confident these technologies offer an exciting new way to address the appearance of fine lines and wrinkles as well as dry, sensitive skin and eczema-like rashes,” said CFO Francisco Salva.<h2 class="st-heading-2">Azitra’s Listing Challenges</h2>Last week, Azitra received a notice from NYSE American LLC for failing to meet its minimum stockholders’ equity requirement of $6 million for companies with recent losses. The company has until April 1, 2027, to regain compliance, during which it will remain listed but will be subjected to regular reviews of its progress.According to Azitra’s latest financial update for the full-year ended Dec. 31, 2025, net loss widened to $11 million from $9 million a year earlier.The company also said it expects to report the topline Phase 1b results for its lead candidate, ATR12-351, for the treatment of Netherton, a rare and severe genetic skin disorder, in the second half of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday surge, retail sentiment has remained in the ‘bearish’ zone over the past 24 hours.One user said the stock could climb over $1 on the daily chart if the volume holds.<stembedurl>https://stocktwits.com/TonyStacks/message/648079663</stembedurl>Nearly 230 million shares changed hands in the first 20 minutes of trading, compared with an average of 1.8 million, according to Stocktwits data.Year-to-date, the stock has gained around 23%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/apple-aapl-stock-downtrend-200dma-retail-concern/cZ3XqspRILL">AAPL Stock’s Decline Leads It Toward 200-DMA For First Time In Over 7 Months – Retail Concerned Over Lack Of Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

This Nano-Cap Pharma Stock Surged 80% Days After A Listing Warning — What’s Fueling the Rally?

The stock crossed its 100-DMA for the first time in more than eight months after announcing a private placement to raise over $31 million.